All Resources
Announcements
Contributed Content
Expert Commentary
Garri Zmudze Insights
CONTRIBUTED CONTENT
Garri contributes op-eds and original content for leading outlets across web3, health, startups, and more.
LinkedIn: What 60-year-old Ironman athletes tell us about our longevity
Longevity will transform how aging looks in society. It will add life to our years, especially later in life.
Contributed Content
·
20 min
·
March 23, 2023
LinkedIn: Take your first steps into the longevity community: Join us at ARDD
Events offer diverse industry actors to align on common goals and seek inspiration from other dedicated individuals. This year’s ARDD event will bring the longevity community together in Copenhagen.
Contributed Content
·
10 min
·
March 7, 2023
Cointelegraph: Artificial intelligence, robots and blockchain deliver next-generation healthcare, today
Emerging technologies are revolutionizing medicine - person by person and pill by pill.
Contributed Content
·
5 min
·
February 16, 2023
Previous
Load More
EXPERT COMMENTARY
Garri is a leading voice for trending topics in the field of health and investing.
LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform
LongeVC invests in Interface Biosciences, securing $3 million for pioneering pharmaceutical development from bacterial natural products, marking a strategic advancement towards critical IND-enabling studies
Expert Commentary
·
5 min
·
Jul 27
BioSpectrum: Seeking the 'fountain of youth'
Garri founded the Longevity Science Foundation to fund the diverse treatments contributing to human longevity.
Expert Commentary
·
4 min
·
Jul 27
Sifted: Purrsonalised health: The startups and VCs betting on pet genetics
Animal genetics market revenue is predicted to exceed $6.4bn by 2027. Here are some of the pet genetics startups to watch.
Expert Commentary
·
1 min
·
Jul 27
Load More
ANNOUNCEMENT
Stay up-to-date with the latest from Garri and the companies within his realm.
Longevity.Technology: The time is right for specialist Longevity investment
Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.
Announcements
·
2 min
·
Jul 27
Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health
Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.
Announcements
·
7 min
·
Jul 27
ARDD: Decentralized science and blockchain in aging research
Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.
Announcements
·
4 min
·
Jul 27
Load More
ALL RESOURCES
Content at the cutting-edge of health and technology.
Sifted: Purrsonalised health: The startups and VCs betting on pet genetics
Animal genetics market revenue is predicted to exceed $6.4bn by 2027. Here are some of the pet genetics startups to watch.
Expert Commentary
·
1 min
·
Jul 27
Green Market Report: Can psychedelics combat aging in humans?
Longevity researchers are looking to psychedelics as an avenue for unlocking new understanding about aging and brain health.
Expert Commentary
·
2 min
·
Jul 27
Labiotech.eu: 5 reasons why collaboration is important in research
Collaboration in biotech will drive the future of the industry. Nonprofits, VCs, and startups must cooperate for success.
Expert Commentary
·
7 min
·
Jul 27
Forbes: Meet a VC on a mission to support women in longevity
Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.
Expert Commentary
·
2 min
·
Jul 27
Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?
Garri shares insights on the current state of biotech venture capital, including overvaluations, recent deals, and the impact of events like the SVB collapse.
Expert Commentary
·
2 min
·
Jul 27
Clinical Leader: Decentralization, it's more than you think
Decentralization encourages transparency, inclusion, and new funding streams for clinical research.
Expert Commentary
·
6 min
·
Jul 27
Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI
AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.
Expert Commentary
·
1 min
·
Jul 27
AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger
I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform
Expert Commentary
·
4 min
·
Jul 27
Wall Street Journal: The Clues to Longer Life That Are Coming From Dogs
Scientists are researching dog aging, including supplement trials and genetic analysis, to unlock a greater understanding of human longevity.
Expert Commentary
·
1 min
·
Jul 27
DealStreet Asia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth
In a recent interview for DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II.
Expert Commentary
·
2 min
·
Jul 27
Previous
Load More
LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform
BioSpectrum: Seeking the 'fountain of youth'
Sifted: Purrsonalised health: The startups and VCs betting on pet genetics